Patient characteristics (peripheral blood samples)
| Patient . | Rai stage . | WBC, 109/L . | Lymphocytes, % . | CD5+/ CD19+, %* . | CD3+, % . | IgVH† mutational status . | p53 status‡ . | CD38 (CD20+), % . | Chromosomal abnormalities§ . |
|---|---|---|---|---|---|---|---|---|---|
| CLL 01 | II | 113.0 | 90.0 | 88.3 | 4.4 | + | Functional | 81 | None |
| CLL 07 | I | 93.3 | 86.9 | 96.8 | 2.4 | + | Functional | 87 | 11q− |
| CLL 08 | 0 | 58.5 | 91.0 | 92.7 | 4.3 | + | ND | 24 | None |
| CLL 11 | II | 49.3 | 88.8 | 91.4 | 5.5 | − | Functional | 92 | 13q− |
| CLL 12 | I | 72.2 | 86.3 | 93.0 | 5.0 | + | Functional | 33 | None |
| CLL 16 | II | 80.1 | 73.7 | 92.0 | 6.0 | + | ND | 39 | 13q− |
| CLL 17 | II | 102.0 | 92.1 | 93.3 | 4.1 | − | ND | 47 | None |
| CLL 18 | 0 | 48.0 | 89.2 | 90.5 | 7.7 | + | ND | 29 | ND |
| CLL 20 | II | 61.4 | 89.0 | 95.0 | 4.0 | + | Functional | 20 | ND |
| CLL 21 | IV | 60.6 | 89.8 | 86.7 | 3.1 | − | ND | 24 | ND |
| CLL 22 | I | 60.1 | 94.4 | 81.7 | 6.5 | − | Dysfunctional | 44 | 17p− |
| CLL 23 | IV | 137.0 | 94.8 | 83.5 | 3.8 | + | Dysfunctional | 57 | 17p−;13q− |
| CLL 25 | I | 79.0 | 93.3 | 84.7 | 3.4 | − | Dysfunctional | 39 | 17p− |
| CLL 29 | I | 117.0 | 95.8 | 95.0 | 1.5 | + | ND | 9.5 | ND |
| CLL 31 | II | 68.8 | 94.7 | 90.8 | 4.7 | + | ND | 1.9 | 13q− |
| CLL 32 | 0 | 73.8 | 86.9 | 85.2 | 7.2 | + | ND | 2.4 | ND |
| CLL 40 | IV | 232.0 | 96.1 | 98.5 | 1.2 | − | ND | 97 | ND |
| Patient . | Rai stage . | WBC, 109/L . | Lymphocytes, % . | CD5+/ CD19+, %* . | CD3+, % . | IgVH† mutational status . | p53 status‡ . | CD38 (CD20+), % . | Chromosomal abnormalities§ . |
|---|---|---|---|---|---|---|---|---|---|
| CLL 01 | II | 113.0 | 90.0 | 88.3 | 4.4 | + | Functional | 81 | None |
| CLL 07 | I | 93.3 | 86.9 | 96.8 | 2.4 | + | Functional | 87 | 11q− |
| CLL 08 | 0 | 58.5 | 91.0 | 92.7 | 4.3 | + | ND | 24 | None |
| CLL 11 | II | 49.3 | 88.8 | 91.4 | 5.5 | − | Functional | 92 | 13q− |
| CLL 12 | I | 72.2 | 86.3 | 93.0 | 5.0 | + | Functional | 33 | None |
| CLL 16 | II | 80.1 | 73.7 | 92.0 | 6.0 | + | ND | 39 | 13q− |
| CLL 17 | II | 102.0 | 92.1 | 93.3 | 4.1 | − | ND | 47 | None |
| CLL 18 | 0 | 48.0 | 89.2 | 90.5 | 7.7 | + | ND | 29 | ND |
| CLL 20 | II | 61.4 | 89.0 | 95.0 | 4.0 | + | Functional | 20 | ND |
| CLL 21 | IV | 60.6 | 89.8 | 86.7 | 3.1 | − | ND | 24 | ND |
| CLL 22 | I | 60.1 | 94.4 | 81.7 | 6.5 | − | Dysfunctional | 44 | 17p− |
| CLL 23 | IV | 137.0 | 94.8 | 83.5 | 3.8 | + | Dysfunctional | 57 | 17p−;13q− |
| CLL 25 | I | 79.0 | 93.3 | 84.7 | 3.4 | − | Dysfunctional | 39 | 17p− |
| CLL 29 | I | 117.0 | 95.8 | 95.0 | 1.5 | + | ND | 9.5 | ND |
| CLL 31 | II | 68.8 | 94.7 | 90.8 | 4.7 | + | ND | 1.9 | 13q− |
| CLL 32 | 0 | 73.8 | 86.9 | 85.2 | 7.2 | + | ND | 2.4 | ND |
| CLL 40 | IV | 232.0 | 96.1 | 98.5 | 1.2 | − | ND | 97 | ND |
Patient data for the lymph node samples used in this study can be found in Smit et al.10
ND indicates not determined.
Percentage of cells positive for CD5 and CD19 surface expression.
Mutated IgVH gene (+) denotes more than 2% mutations compared with germline sequence.
p53 functional status was measured via radiation-induced RNA expression of p53 target genes Puma and Bax, or by p53 and p21 protein up-regulation via Western blot, as decribed in Mackus et al16 and Pettitt et al.25 Patient 25 had a so-called type A dysfunction.
As determined by FISH. Probes for 11q22.3 (ATM), 13q14 (D13S319), and 17p13 (TP53) were obtained from Abbott-Vysis. Samples with more than10% aberrant signals were considered abnormal.